Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization
10 Dec 2024
The post-pandemic burden of COVID-19 remains significant in adults. Four studies from IDWeek 2024 highlight the benefits of nirmatrelvir-ritonavir (NMV/r) for high-risk adults with SARS-CoV-2 immunity and link chronic conditions to COVID-19 hospitalization. Identifying high-risk patients and using NMV/r in outpatient settings can reduce severe outcomes.
Resources
Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization
Nirmatrelvir-ritonavir efficacy and risk factors for COVID-19 hospitalization